Merck’s Baby Biotech Splurge Won’t Fix Its Reliance on Keytruda

(Bloomberg Opinion) -- Merck & Co. seems to have it in for investment bankers, at least when it comes to potential IPO fees. The drug giant announced Monday that it was buying closely held cancer-t...